Disease relapse is the most common reason for treatment failure of both autologous (auto) and allogeneic (alio) blood and marrow transplantation (BMT). As such, there is the unmet need to augment antitumor immunity in these settings. We propose a novel adoptive cell therapy (ACT) approach to augment antitumor immunity after autoBMT and to treat the post-transplant relapse after alloBMT by exploiting the unique characteristic of the bone marrow as both the primary anatomic site for most hematologic malignancies and a compartment enriched with tumor-reactive marrow infiltrating lymphocytes (MILs). We hypothesize that ex vivo activated tumor-specific MILs can impart measurable and sustainable antitumor immunity upon adoptive transfer. This hypothesis is formulated on the basis of our preliminary data and by bringing together innovative strategies developed during the previous funding cycle. MILs from multiple myeloma patients can be expanded ex vivo with anti-CD3/CD28 stimulation and activated as to significantly Increase their tumor specificity in ACT studies. Similarly, MILs obtained from patients undergoing alloBMT using PTCy-based GVHD prophylaxis can also be expanded, using the same techniques and augment their antitumor reactivity. Accordingly, in Specific Aim #1, we will determine if activated MILs in combination with an allogeneic myeloma cell vaccine or lenalidomide can augment and/or sustain antitumor immunity after autoBMT and assess the impact of activated MILs on immune reconstitution, tumor-specific immunity and correlate these parameters with clinical responses.
In Specific Aim #2, we will conduct a phase l/ll clinical trial to evaluate the feasibility/safety of alloMILs obtained from the patient as a more tumor-specific

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (J1))
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Robinson, Tara M; O'Donnell, Paul V; Fuchs, Ephraim J et al. (2016) Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53:90-7
Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:10-24
Robinson, Tara M; Fuchs, Ephraim J (2016) Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol 23:524-529
DeZern, Amy E; Williams, Katherine; Zahurak, Marianna et al. (2016) Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion 56:1750-7
Gerber, Jonathan M; Zeidner, Joshua F; Morse, Sarah et al. (2016) Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes. Haematologica 101:607-16
Lombardi, Lindsey R; Kanakry, Christopher G; Zahurak, Marianna et al. (2016) Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma 57:666-75
Gondek, L P; Zheng, G; Ghiaur, G et al. (2016) Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 30:1916-20
Kanakry, Christopher G; Coffey, David G; Towlerton, Andrea M H et al. (2016) Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 1:
Alonso, Salvador; Hernandez, Daniela; Chang, Yu-Ting et al. (2016) Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. J Clin Invest 126:4460-4468
Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:132

Showing the most recent 10 out of 436 publications